

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Box Missing Parts, Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: 7/15/02 Signature: [Signature]
(Brent LaBarge)

Docket No.: GPCG-P01-003
(PATENT)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Nagy et al.

Application No.: 10/001934

Group Art Unit: 1644

Filed: November 15, 2001

Examiner: Not Yet Assigned

For: HUMAN POLYPEPTIDES CAUSING OR
LEADING TO THE KILLING OF CELLS
INCLUDING LYMPHOID TUMOR CELLS

RESPONSE TO NOTICE TO FILE MISSING PARTS OF APPLICATION

Box Missing Parts
Commissioner for Patents
Washington, DC 20231

Dear Sir:

In response to the Notice to File Missing Parts of Application – Filing Date Granted mailed January 15, 2002, Applicant respectfully submits a Combined Declaration and Power of Attorney, the Filing Fee for the Application (as shown on accompanying Fee Transmittal), and Formal Drawings (14 figures, 57 pages).

Please charge our Deposit Account No. 18-1945 in the amount of \$5,462.00 covering the fee set forth in 37 CFR 1.16(e) and the filing fee for the above-referenced application. The Commissioner is hereby authorized to credit any overpayments or to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. GPCG-P01-003. A duplicate copy of this paper is enclosed.

Dated: July 15, 2002

Respectfully submitted,

By [Signature]

David P. Halstead, Ph.D.

Registration No.: 44,735

ROPES & GRAY

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

08/06/2002 NPRASASD 00000006 181945 10001934

01 FC:118

1440.00 CH

10001934-071002



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: July 15, 2002

Signature:

(Brent LaBarge)

Docket No.: GPCG-P01-003
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Nagy et al.

Application No.: 10/001934

Group Art Unit: 1644

Filed: November 15, 2001

Examiner: Not Yet Assigned

For: HUMAN POLYPEPTIDES CAUSING OR
LEADING TO THE KILLING OF CELLS
INCLUDING LYMPHOID TUMOR CELLS

SUBMISSION OF FORMAL DRAWINGS

Commissioner for Patents
Washington, DC 20231


Dear Sir:

Submitted herewith is one set (fifty-seven sheets, fourteen figures) of formal drawings for filing in the above-identified patent application. Kindly substitute the enclosed formal drawings for the informal drawings submitted with the originally filed application.

Applicant believes no fee other than the fees paid in response to the Notice to File Missing Parts of Nonprovisional Application is due with this response. However, if an additional fee is due, please charge our Deposit Account No. 18-1945, under Order No. GPCG-P01-003 from which the undersigned is authorized to draw.

Dated: July 15, 2002

Respectfully submitted,

By 

David P. Halstead, Ph.D.

Registration No.: 44,735

ROPES & GRAY

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000


(617) 951-7050 (Fax)

Agents for Applicant

AMINO ACID AND NUCLEOTIDE SEQUENCE LISTING FOR A PATENT APPLICATION

Electronic Version 1.0.1

Stylesheet Version 1.0.1



STATEMENT REGARDING SEQUENCE(S)

This is a request for filing the electronic copy of a sequence listing for a patent application under 37 C.F.R. 1.821-1.825.

This communication has an attached file which is the electronic copy of the amino acid and/or nucleotide sequence listing for the previously mentioned United States Patent Application.

The electronic copy submitted herewith is the Computer Readable Form (CRF), as required by 1.821(e).

Any applicable fees associated with the filing of the electronic copy have been paid.

This submission does not go beyond the disclosure of the application as originally filed (i.e., contains no new matter). It may be in addition to an original CRF, filed to comply with the sequence rules.

This submission in electronic form comprises only the CRF of 37 C.F.R. 1.821(e). Applicant is responsible for all additional requirements of amino acid and/or nucleotide sequence listing submissions as specified in 37 C.F.R. 1.821 - 1.825.

This submission does not go beyond the disclosure of the application as originally filed (i.e., contains no new matter), and/or is in addition to an original CRF filed to comply with the sequence rules. If not made to comply with an originally filed CRF, it is identical to the sequences disclosed in the application as originally filed and/or the paper copy of the Sequence Listing as originally filed.

Attachment Description:
CRF Biosequence

TRANSMITTAL FORM

Electronic Version 1.0.3

Stylesheet Version: 1.0

Submission Type: BIO

Sequence Filing

Application Number: 10/001,934

Attorney Docket
Number: GPCG-P01-003

Human Polypeptides Causing or Leading to the Killing of Cells Including Lymphoid Tumor Cells

First Named Inventor: Zoltan Nagy

SUBMITTED BY

Name:	David P. Halstead
Registration Number:	44,735
Electronic Signature Mark: DYH	Date Signed: 20020715

I certify that the use of this system is for OFFICIAL correspondence between patent applicants or their representatives and the USPTO. Fraudulent or other use besides the filing of official correspondence by authorized parties is strictly prohibited, and subject to a fine and/or imprisonment under applicable law.

I, the undersigned, certify that I have viewed a display of document(s) being electronically submitted to the United States Patent and Trademark Office, using either the USPTO provided style sheet or software, and that this is the document(s) I intend for initiation or further prosecution of a patent application noted in the submission. This document(s) will become part of the official electronic record at the USPTO.

Attached Files:

sequence-listing	GPCG-P01-003SequenceListing.APP
biotechnology-listing-filing	GPCG-P01-003SequenceListingbio.xml

I hereby certify that this correspondence is being transmitted to the Patent and Trademark Office on the following date. 2002-07-15

Name: David P. Halstead

Electronic Signature Mark: DYH

Comments:

Acknowledgment Receipt:

SUBMISSION TYPE: **BIO Sequence Filing**

APPLICATION NUMBER: **10001934**

FIRST NAMED INVENTOR: **Zoltan Nagy**

TITLE OF INVENTION: **Human Polypeptides Causing or Leading to the
Killing of Cells Including Lymphoid Tumor Cells**

ATTORNEY DOCKET NUMBER: **GPCG-P01-003**

FILE LISTING:

transmittal	tranGPCG-P01-003SequenceListing.xml 6379 Bytes
sequence-listing	GPCG-P01-003SequenceListing.APP 52859 Bytes
biotechnology-listing-filing	GPCG-P01-003SequenceListingbio.xml 957 Bytes
biotechnology-listing-filing	u-bio.dtd 3619 Bytes
biotechnology-listing-filing	e-bioseq.xsl 6067 Bytes

EFS ID: **16432**

FILE SIZE: **23876 Bytes**

TIMESTAMP: **Mon Jul 15 19:14:39 EDT 2002**

MESSAGE DIGEST: **GsVsEQxaOHrN8Q80Lr4rBw==**

DIGITAL CERTIFICATE HOLDER NAME: **cn=David P. Halstead, ou=Registered Attorneys**

UPLOAD STATUS: **You have successfully uploaded your submission to USPTO**



UNITED STATES PATENT AND TRADEMARK OFFICE

JUL 18 2002

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/001,934	11/15/2001	Zoltan Nagy	GPCG-P01-003

CONFIRMATION NO. 8886

FORMALITIES LETTER



OC000000007312762

28120

ROPES & GRAY

ONE INTERNATIONAL PLACE

BOSTON, MA 02110-2624

07/22/2002 EAREGAY1 00000080 181945 10001934

01 FC:201 370.00 CH
 02 FC:202 378.00 CH
 03 FC:203 4509.00 CH
 04 FC:205 65.00 CH
 05 FC:204 140.00 CH

Date Mailed: 01/15/2002

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.
Applicant must submit \$ 370 to complete the basic filing fee for a small entity.
- Total additional claim fee(s) for this application is \$5027.
 - \$4509 for 501 total claims over 20.
 - \$378 for 9 independent claims over 3.
 - \$140 for multiple dependent claim surcharge.
- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(l) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.
- **The balance due by applicant is \$ 5462.**

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- Substitute drawings in compliance with 37 CFR 1.84 because:
 - drawing sheets do not have the appropriate margin(s) (see 37 CFR 1.84(g)). Each sheet must include a top margin of at least 2.5 cm. (1 inch), a left side margin of at least 2.5 cm. (1 inch), a right side margin of at least 1.5 cm. (5/8 inch), and a bottom margin of at least 1.0 cm. (3/8 inch);
- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at

63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY